Please login to the form below

Not currently logged in

Crohn's Disease

This page shows the latest Crohn's Disease news and features for those working in and with pharma, biotech and healthcare.

Celgene to launch five new products through to 2020

Celgene to launch five new products through to 2020

The five are all “potential blockbusters”, according to Celgene’s chief executive Mark Alles on the company’s third-quarter results call. ... registration trial in this indication – TRUE NORTH – as well as studies in Crohn’s disease.

Latest news

  • BMS CEO tackles investor ‘frustrations’ on immuno-oncology BMS CEO tackles investor ‘frustrations’ on immuno-oncology

    BMS also highlighted new data with BMS’selective TYK2 inhibitor for moderate to severe plaque psoriasis, which has moved into phase 3 and is also in mid-stage testing for ... s disease, ulcerative colitis and lupus.

  • First Humira biosimilars reach EU market First Humira biosimilars reach EU market

    AbbVie’s patent protection for Humira (adalimumab) has come to an end in Europe. ... diseases including rheumatoid arthritis, psoriasis and Crohn's disease.

  • Gilead and Galapagos JAK contender scores in RA trial Gilead and Galapagos JAK contender scores in RA trial

    The results are further good news for the partners and their inflammatory conditions contender, which is also being studied in ulcerative colitis, Crohn’s disease and ankylosing spondylitis. ... John McHutchinson. John McHutchison, MD, chief scientific

  • BMS psoriasis drug hits the mark in phase II BMS psoriasis drug hits the mark in phase II

    presence than BMS in the inflammatory disease market. ... BMS also has phase II studies of the drug ongoing in other indications including systemic lupus erythematosus and Crohn's disease.

  • Gilead, Galapagos JAK inhibitor clears phase II test Gilead, Galapagos JAK inhibitor clears phase II test

    The drug is also in development for rheumatoid arthritis (RA), ulcerative colitis and Crohn’s disease with phase III trials already underway in those indications and results due in the coming ... Like filgotinib, upadacitinib is also being tested in a

More from news
Approximately 19 fully matching, plus 158 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    for local administration for the treatment of complex perianal fistulas in patients with Crohn’s disease. ... Option exercise (2 options). 640. TiGenix/Takeda. Cx601, lead asset, allogeneic expanded adipose-derived stem cells (eASC) locally

  • The good, the bad and the ugly The good, the bad and the ugly

    Tecfidera (MS) and Spinraza (Spinal Muscular Atrophy) are expected to generate big sales, while Tysabril (MS and Crohn’s Disease) and Avonex (MS) are expected to see sales drop due to ... However, there is a movement towards greater research in this

  • Managing medication non-adherence Managing medication non-adherence

    Autoimmune conditions such as Crohn’s disease can flare up through an imbalance of things like stress, lack of sleep or overworking - not just as a direct consequence of nonadherence to ... These will be used to aid in decision-making and help

  • Deal Watch January 2017 Deal Watch January 2017

    Pipping Sanofi to the post, the acquisition brings a high margin rare disease portfolio at the cost of $280 per share representing a 23% premium. ... Assembly Biosciences. Allergan. Exclusive global licence . 2 pc candidates for ulcerative colitis

  • Deal Watch October 2016 Deal Watch October 2016

    How many Beatles song titles did you spot in this month's Deal Watch report? ... Allergan (US). Licence. Anti-interleukin 23 MAb in phase IIb for Crohn's Disease.

More from intelligence
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest appointments

  • TiGenix appoints Dr Marie Paule Richard TiGenix appoints Dr Marie Paule Richard

    in phase III trials for complex perianal fistulas in Crohn's disease.

  • Ex J&J VP joins board of Immune Ex J&J VP joins board of Immune

    Immune will benefit from Durrant's knowledged of the iundstry gained during time in roles such as worldwide VP at Johnson &Johnson and VP, Pharmacia until its acquisition by Pfizer. ... Its lead product candidate is bertilimumab, which is in clinical

  • Former Novartis president joins Qu Biologics Former Novartis president joins Qu Biologics

    His senior industry experience will support Qu Biologics' plans to advance the development of its investigational immunotherapies for treatments such as Crohn's disease. “ ... Bob Pelzer's wealth of leadership experience with Novartis and DuPont will

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Smart Pill Technologies Market: Global Industry Analysis and Opportunity Assessment by 2025

    Prevalence of Crohn's disease is 201 per 100, 000 adults and Ulcerative colitis is 238 per 100, 000 adults. ... The rising geriatric population will also act as a driver since this segment of population is more prone to IBD, Ulcerative colitis and

  • Sales of Autoimmune Disease Therapeutics Market to Witness a Decline By the End of 2026

    Some of the common types of autoimmune diseases are Crohn's disease, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, and with rising prevalence of autoimmune diseases the demand ... According to

  • Patient Perspective: Crohn's disease

    Patient Perspective: Crohn's disease. At Synergy Vision, we aim to make a difference to patients. ... In the first of our series on patient perspectives we are talking about Crohn's disease.


    THE OTHER SIDE OF… CROHN’ S DISEASE. “ After visiting about seven doctors in two different countries, I am confident to say that all can align on 2– 3 points at most”. ... Meet Irene. Like millions of others worldwide (and an estimated 115, 000

  • Living with Crohn's Report

    Living with Crohn's Report. Are you looking for a deeper understanding of the emotional needs, behaviours and treatment programmes of patients living with Crohn’ s Disease? ... Living with Crohn’ s is a new syndicated report designed to provide an in

More from PMHub
Approximately 7 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...